盘状蛋白结构域受体 (DDR) 是跨膜受体酪氨酸激酶 (RTK) 超家族的成员,与其他受体的区别在于,盘状蛋白结构域中存在盘状蛋白基序,并且利用胶原蛋白作为内部配体。已鉴定出两种类型的 DDR,即 DDR1 和 DDR2,具有不同的表达谱和配体特异性。
与胶原蛋白结合后,DDR 会传导涉及各种细胞功能的细胞信号,包括细胞粘附、增殖、分化、迁移和基质稳态。由突变或过表达导致的 DDR 功能改变与多种疾病有关,包括动脉粥样硬化、炎症、癌症和组织纤维化。DDR 已被视为药物发现的新型潜在分子靶点,并且人们正在加大力度,以识别针对该受体的新型小分子抑制剂。
Discoidin domain receptors (DDRs) are members of the transmembrane receptor tyrosine kinase (RTK) superfamily which are distinguished from others by the presence of a discoidin motif in the extracellular domain and their utilization of collagens as internal ligands. Two types of DDRs, DDR1 and DDR2, have been identified with distinct expression profiles and ligand specificities.
Upon collagen binding, DDRs transduce cellular signaling involved in various cell functions, including cell adhesion, proliferation, differentiation, migration, and matrix homeostasis. Altered DDR function resulting from either mutations or overexpression has been implicated in several types of disease, including atherosclerosis, inflammation, cancer, and tissue fibrosis. DDRs have been considered as novel potential molecular targets for drug discovery and increasing efforts are being devoted to the identification of new small molecule inhibitors targeting the receptors.
LLC355 是一种盘状结构域受体 1 (DDR1) ATTEC 降解剂,可有效降解 DDR1 蛋白(在非小细胞肺癌 NCI-H23 细胞中的 DC50 值为 150.8 nM),通过溶酶体介导的自噬诱导 DDR1 降解,并可有效抑制癌细胞的致瘤性、迁移和侵袭。
PROTAC DDR1 degrader-1 是一种强效、选择性靶向 DDR1 的 PROTAC 降解剂,可通过泛素-蛋白酶体系统选择性诱导全长 DDR1 降解、阻断下游信号通路,抑制肿瘤细胞迁移与侵袭,并在小鼠体内展现抗肿瘤活性,可用于 DDR1 驱动型癌症的研究(粉色:DDR1 配体 (MS-O18511);蓝色:Cereblon 配体 (MS-M39064);黑色:连接子 (MS-Y46932))。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号